Acroxen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acroxen

Property Description
Active Ingredient Naproxen Sodium
Form Oral Tablet (Film-Coated)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Relief from pain, inflammation, and fever
Origin Synthetic Compound (Arylpropionic Acid Derivative)

What Type of Medicine is Acroxen?

Acroxen is a pharmaceutical preparation delivered as an oral tablet and is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its core component is the active ingredient Naproxen Sodium, which is the fast-acting sodium salt form of Naproxen. This classification identifies it as a systemic medication used primarily to modulate the body's processes involving pain, inflammation, and fever. The NSAID class is clinically recognized for its combined analgesic, anti-inflammatory, and antipyretic properties, which define its therapeutic group.

Composition, Form, and Origin

The medicinal efficacy of Acroxen stems from the presence of Naproxen Sodium. This specific formulation, the sodium salt of Naproxen, is a key differentiating factor; it is chemically distinct from the Naproxen base and is engineered to achieve rapid absorption into the bloodstream following the oral route of administration. Chemically, this compound is a synthetic entity that belongs to the arylpropionic acid family. Acroxen is manufactured as a single-ingredient product, and this particular salt formulation ensures that the active ingredient quickly reaches the systemic circulation, a property often prioritized for acute discomfort. The compound's properties include an inhibitory effect on prostaglandins, which establishes its role in reducing inflammation.

General Purpose and Physiological Action

The general purpose of Acroxen is to provide simultaneous symptomatic relief by leveraging its inherent analgesic, anti-inflammatory agent, and antipyretic properties. Its action is achieved through inhibition of prostaglandin synthesis, which are key chemical messengers responsible for amplifying pain signals and triggering localized inflammation throughout the body. This systemic effect allows the medicine to broadly address physical discomfort, reduce swelling, and help bring down an elevated body temperature.

What side effects are possible with Acroxen?

Possible Side Effects and Safety Information

Acroxen (Naproxen/Naproxen Sodium) is an Nonsteroidal Anti-inflammatory Drug (NSAID) with important regulatory safety warnings based on its pharmacological class. All NSAIDs carry a Boxed Warning regarding the potential for serious adverse events.

Serious Adverse Reactions and Warnings

System-Organ Class Serious Adverse Reaction (Examples)
Cardiovascular Increased risk of serious thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Risk may increase with duration and dosage. Contraindicated for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Gastrointestinal (GI) Increased risk of serious GI events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These can occur without warning symptoms. Elderly patients are at greater risk.
Hypersensitivity Severe allergic reactions (anaphylaxis) and serious skin reactions (e.g., Stevens-Johnson Syndrome). Contraindicated in patients with a history of aspirin-sensitive asthma or allergic reactions to other NSAIDs.
Organ Toxicity Hepatotoxicity, renal toxicity, and potential for exacerbation of heart failure or hypertension.

Commonly Reported Adverse Reactions

The most frequently reported adverse reactions generally involve the gastrointestinal and nervous systems. These include dyspepsia, heartburn, stomach pain, nausea, headache, dizziness, and drowsiness. The risk of serious GI events is considered constant throughout the treatment period, increasing with higher doses.

Population-Specific Safety Considerations

  • Pregnancy: Use must be avoided starting at 30 weeks gestation due to the risk of premature closure of the fetal ductus arteriosus.
  • Elderly Patients: This population has a greater risk for serious GI adverse events and may require closer monitoring and dose adjustments.
  • Fertility: Use may be associated with reversible infertility in women and should be considered for withdrawal in those having difficulty conceiving.

Overdose and Emergency Response

The regulatory profile for Acroxen (Naproxen Sodium) overdose is defined by the potential for progressive systemic toxicity. Documented initial manifestations may include gastrointestinal disturbances such as nausea, vomiting, and epigastric pain, as well as Central Nervous System (CNS) effects including drowsiness, confusion, dizziness, and severe headache. Tinnitus (ringing in the ears) is also listed.

The primary concern is the potential for progression to severe or life-threatening systemic outcomes. These include Gastrointestinal bleeding and perforation, acute renal failure, and serious CNS events such as seizures and coma. Patients with pre-existing conditions, particularly the elderly and those with impaired renal or cardiac function, face an increased risk of severe adverse events.

This potential for rapid deterioration necessitates that regulators mandate seeking immediate medical attention upon suspected overdose. You must contact emergency services or a Poison Control Center right away. No specific antidote is known for this NSAID overdose; therefore, management is confined to symptomatic and supportive treatment. This care includes measures like activated charcoal and close hospital monitoring of vital signs, renal function, and acid-base status to manage the systemic effects.

Therapeutic Uses of Acroxen

What Acroxen Treats: Main Uses and Benefits

Acroxen is primarily used in situations involving certain symptoms related to inflammatory or irritative states. It is generally applied across domains where additional symptomatic support is needed, addressing pain, swelling, and fever. It is relevant for easing these symptoms in situations where patients experience discomfort.

The medication is commonly used across conditions involving episodic or fluctuating manifestations, such as the inflammatory symptoms of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gouty arthritis flares, and the discomfort of primary dysmenorrhea (menstrual cramps). It is also applied in acute clinical scenarios such as sprains, strains, tendinitis, and general back pain.

Acroxen helps address the groups of symptoms that include persistent joint pain, swelling, and stiffness. This provides support that helps ease the overall symptom burden during acute phases, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

“Applied in clinical settings that involve acute or unstable symptom patterns, Acroxen is used for managing the significant distress from inflammatory discomfort.”

Quick Fact: Relief for Inflammation
Acroxen is considered relevant in contexts marked by increased discomfort and swelling, helping to manage both acute flares and the persistent symptoms of chronic inflammatory conditions.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Acroxen?

Eligibility for Acroxen (Naproxen Sodium) is strictly defined by regulatory documents, focusing on patient health status and demographics.

Populations Who Must Not Use Acroxen (Contraindications)

Acroxen is strictly contraindicated for several groups. This medicine must not be used by individuals with a known hypersensitivity to naproxen or a history of allergic reactions (like asthma or hives) to aspirin or any other NSAID. Absolute prohibitions also apply to patients in the setting of Coronary Artery Bypass Graft (CABG) surgery, and those with active gastrointestinal ulceration/bleeding or severe heart, hepatic, or renal failure.

Age and Condition-Based Restrictions

Population Group Regulatory Eligibility Status
Pediatric Patients Not established for children under two years of age. OTC use is for those 12 years and older; prescription use starts at 2 years for specific conditions.
Pregnancy Contraindicated in the third trimester (30 weeks gestation and later) due to fetal risk. Use is not recommended for women attempting to conceive.
Older Adults Use requires caution due to increased susceptibility to adverse effects; the lowest effective dose should be used.
Impaired Organ Function Use is conditional for those with non-severe renal or hepatic impairment, requiring monitoring and potential dose adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions of Acroxen (Naproxen Sodium) as documented in authoritative government regulatory sources.

Contraindicated Combinations and Restrictions

Acroxen is strictly contraindicated for the management of pain in the peri-operative setting of coronary artery bypass graft (CABG) surgery. Use is also restricted for individuals with a history of allergic-type reactions to Aspirin or any other nonsteroidal anti-inflammatory drugs (NSAIDs). Co-administration with analgesic doses of other NSAIDs is not generally recommended due to the cumulative risk of adverse effects.

Pharmacodynamic (PD) Interactions

Co-administration with agents that interfere with blood clotting, such as Warfarin and other anticoagulants, or with SSRIs and corticosteroids, is associated with an increased risk of serious gastrointestinal bleeding. Furthermore, Naproxen may diminish the therapeutic effect of certain antihypertensive medications, including ACE inhibitors, ARBs, and beta-blockers. It can also reduce the natriuretic effect of diuretics (Furosemide and Thiazides).

Pharmacokinetic (PK) and Exposure Modification

The regulatory profile documents that Naproxen may reduce the renal clearance of certain co-administered drugs. For example, it decreases the clearance of Lithium, potentially causing elevated plasma levels. Naproxen can also inhibit the tubular secretion of Methotrexate, which may enhance its toxicity. Conversely, Probenecid is documented to significantly increase Naproxen’s own plasma levels and extend its half-life. Antacids and Sucralfate may delay Naproxen absorption.

Substance and Condition Notes

Combining Acroxen with alcohol is associated with an increased risk of serious gastrointestinal bleeding. A caution exists for concomitant use with ACE inhibitors or ARBs in elderly or volume-depleted patients due to the potential for deterioration of renal function.

Mechanism of Action

Acroxen (Naproxen Sodium) exerts its effect by acting as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, a crucial step within the body's lipid-signaling pathways. This molecular interference dampens the biosynthesis of key physiological mediators, which defines the resulting physiological consequences.

Inhibiting the Prostaglandin Synthesis Cascade

The core mechanism involves binding to and blocking the active sites of both COX-1 and COX-2 enzymes, thereby preventing the conversion of arachidonic acid into prostaglandins and other related eicosanoids. This action targets the underlying chemical cascade responsible for initiating and propagating signaling within nociceptive and inflammatory pathways.

️ Dual Action on Thermoregulation and Nociceptive Signaling

By limiting the production of Prostaglandin E2 ( PGE2), the mechanism simultaneously influences two critical systems: it reverses the elevation of the body's hypothalamic thermal setpoint in the central nervous system, and it decreases the chemical sensitization of peripheral pain receptors (nociceptors). This targeted PGE2 modulation results in the modulation of central thermal control and diminished nociceptive pathway signaling.

Systemic Dampening of Inflammatory Responses

The resulting physiological change is the systemic suppression of the prostaglandin-driven components of inflammation, such as vasodilation and increased capillary permeability. This establishes a modulated state within the localized tissue response, resulting in the limitation of fluid and cellular accumulation.

Dosage and Administration Information

Acroxen, an oral tablet, is administered via the oral route. The overarching principle for its use is the application of the lowest effective dose for the shortest duration consistent with individual treatment goals.

Official Dosing and Frequency

For chronic conditions, the standard daily maintenance dose typically ranges from 500 mg to 1000 mg of Naproxen equivalent, generally administered twice daily (every 12 hours). However, certain controlled-release formulations may be prescribed for a once daily schedule. In acute scenarios, such as pain management or gout, a higher initial dose, like 550 mg Naproxen Sodium, is typically followed by smaller, divided doses, such as 275 mg every 6 to 8 hours as needed. The total daily dose after the first day is generally restricted to 1100 mg Naproxen Sodium.

Administration Protocol and Adjustments

The medicine should be swallowed with a full glass of water and is often taken preferably with or after food to aid administration. Form-specific instructions require that delayed-release or controlled-release tablets not be crushed, cut, or chewed to maintain their intended release profile. A lower dose is typically considered for older adults and for individuals with known renal or hepatic impairment. For pediatric use in juvenile arthritis, the dose is calculated based on body weight, using approximately 10 mg/kg per day, divided into two doses. If a scheduled dose is missed, it is taken as soon as it is recalled, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped to prevent a double dose.

Recent Clinical Evidence

Research Evidence Overview of Studies for Acroxen (Naproxen Sodium)

This section provides a patient-friendly summary of the structured research evidence for Acroxen, based solely on authoritative studies and regulatory documents. It describes what has been studied and what remains uncertain, without offering clinical guidance or making claims about personal outcomes.

Evidence for Use in Chronic Inflammatory Conditions

The research base exploring the use of the medicine in conditions like rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis primarily consists of Randomized Controlled Trials (RCTs). These are high-standard studies where participants are assigned to receive either the study medicine, a placebo, or another established treatment. Studies were conducted in Adults with confirmed diagnoses of these conditions.

Researchers studied outcomes related to physical discomfort and functional imbalance. This involved monitoring patient-reported pain intensity scales, as well as objective measurements of joint swelling and tenderness. Studies monitored outcomes over intermediate periods, typically spanning several weeks, with some research extending to long-term follow-up up to one or two years. Findings describe patterns observed in the studies related to outcomes related to physical discomfort and functional assessments over these defined time intervals.

Evidence for Use in Acute Pain and Inflammatory Flares

Research has also examined the research base involving episodic or acute changes, specifically in acute gouty arthritis flares and primary dysmenorrhea (menstrual cramps). Research exploring these acute changes is largely drawn from short-term, placebo-controlled trials conducted in adult populations experiencing these temporary states of heightened symptom activity.

For acute gout, the research examined outcomes capturing phases of heightened symptom activity, such as measured changes in joint inflammation and acute pain intensity scores over a few days to two weeks. For primary dysmenorrhea, studies monitored patient-reported outcomes describing perceived discomfort, the duration of pain, and the need for supplemental relief over one to two menstrual cycles. Findings describe group patterns related to the outcomes describing episodic or acute changes.

What Remains Uncertain About Acroxen Research

Official documents and systematic reviews identify several gaps and limitations within the overall research landscape. One key limitation is that subgroup findings are uncertain when looking at highly specific patient categories or certain disease severities, meaning the results apply only to the populations studied. Research exploring the use of the medicine in Adults was conducted as the primary population across all indications, though studies have evaluated Adolescents and Older Adults as subgroups.

While research contributes to understanding symptom patterns, comparative evidence against all alternative treatments for every condition may be lacking in head-to-head trials. Finally, due to the nature of the short-term trials used for acute conditions, evidence for long-term outcomes or the durability of the observed responses is not well established.

Key Studies & References

  1. Naproxen - StatPearls - NCBI Bookshelf (Review of Indications and Study Contexts)
  2. A 7-Day Multicenter Randomized Double-Blind, Double-Dummy Parallel Group Trial to Assess the Safety and Efficacy of 400 mg Lumiracoxib Once Daily Versus 500 mg Naproxen Twice Daily in Patients With Acute Musculoskeletal Pain Due to Uncomplicated Soft Tissue Injury (RCT Context)

Frequently Asked Questions (FAQ)

Common questions about Acroxen (FAQ)

Q: How does Acroxen compare to other medicines in the same class?

A: Acroxen’s active ingredient is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Official pharmacological descriptions note that its primary distinction from some other NSAIDs is a longer elimination half-life, generally documented to be between 12 and 17 hours. This longer half-life is described in pharmacological profiles as potentially allowing for twice-daily administration, as described in regulatory documents.


Q: Will I feel different right away after taking Acroxen?

A: The active ingredient in Acroxen is formulated for rapid absorption. Official pharmacokinetic data indicates that the onset of effect typically begins within one hour of taking the medication. Maximum plasma concentrations are generally reached in one to two hours.


Q: Does Acroxen affect sleep patterns?

A: Official information indicates that sleep patterns may be affected by this medicine. Adverse reactions reported in the central nervous system include both drowsiness and, conversely, insomnia. These effects are described in the official product information.


Q: Can I take Acroxen with my blood pressure medicine?

A: Regulatory warnings describe that the active ingredient may diminish the effect of certain antihypertensive medications, including specific drug classes such as ACE inhibitors, ARBs, and beta-blockers. Official labels contain detailed information on these potential interactions.


Q: Are there any vitamins or supplements that interact with Acroxen?

A: The official prescribing information focuses on interactions with other prescription drugs that affect blood clotting or the kidneys. Regulatory labels state that information regarding all co-administered products, including non-prescription medicines, vitamins, and herbal products, should be reviewed due to the potential for unlisted interactions.


Q: What are the official warnings about stopping Acroxen suddenly?

A: Regulatory guidance emphasizes that, like all NSAIDs, the medication should be used for the shortest duration necessary to achieve treatment goals. There are no standard regulatory warnings regarding physical dependence or complex substance withdrawal associated with cessation of this medication.


Q: What kind of evidence supports the use of Acroxen?

A: The medication's approved uses are supported by a research base primarily consisting of Randomized Controlled Trials (RCTs). These studies were conducted to examine outcomes related to physical discomfort and functional improvement in conditions like chronic arthritis and acute pain.


Q: Is Acroxen approved in countries outside the US?

A: The active ingredient, Naproxen, is approved for use by regulatory bodies in several countries beyond the United States. This includes approval for prescription and/or non-prescription use in regions like Europe (UK), Canada, and Australia.


Q: Does Acroxen affect fertility in men or women?

A: Official regulatory information states that the use of this medicine may be associated with reversible infertility in women. Regulatory information notes that if a woman is experiencing difficulty conceiving, discontinuing the use of the medicine should be considered. The effect on male fertility is not a highlighted regulatory warning.


Q: Why do some people need a higher dose of Acroxen than others?

A: Official prescribing information describes that dosage may be adjusted based on several factors outlined in the prescribing information. This includes the condition being addressed (e.g., chronic inflammation versus acute pain) and the specific formulation used (e.g., immediate-release versus controlled-release).


Q: Does Acroxen cause weight gain or loss?

A: Official labels do not list weight gain or loss as common side effects. However, regulatory warnings note that the medicine is associated with fluid retention. Fluid retention is a safety consideration noted in official documents, particularly for individuals with pre-existing heart conditions.


Q: Is it common to feel tired when using Acroxen?

A: Official reports of adverse effects include central nervous system reactions such as dizziness and drowsiness. While 'tiredness' is not always specifically listed, these effects may be perceived by the user as general fatigue or tiredness.


Q: Can Acroxen affect my mood or energy level?

A: Official reports list certain psychiatric and nervous system adverse reactions. These reported effects include confusion, depression, and mood alterations.


Q: Are there any major diet restrictions when taking Acroxen?

A: Official warnings primarily focus on the documented increased risk of gastrointestinal bleeding when the medicine is combined with alcohol. Regulatory documents note that for patients with certain pre-existing conditions, caution regarding sodium or potassium intake may be relevant due to the potential for the medicine to affect fluid retention or potassium levels.


Q: Do certain foods make Acroxen less effective?

A: Official administration guidelines state that taking the medication with food may delay the amount of time it takes for the drug to begin working. This is due to the process of absorption being slowed down by the presence of food in the stomach.


Q: Is it safe to drink coffee while on Acroxen?

A: There is no specific regulatory warning against coffee. Official information notes that the medicine carries a risk of serious gastrointestinal issues, and warnings exist about substances like alcohol that can increase this risk.


Q: How long does Acroxen stay in your system after stopping?

A: The elimination half-life of the active ingredient is officially documented to be between 12 and 17 hours. This means it takes this long for half of the drug to be cleared from the system.


Q: Are there different versions or strengths of Acroxen?

A: Yes, the active ingredient is available in several regulatory-approved forms and strengths. This includes immediate-release, delayed-release, and controlled-release tablets, and it is offered in different milligram amounts.


Q: Can people with kidney problems use Acroxen?

A: The medication is strictly contraindicated in cases of severe renal failure. For individuals with non-severe renal impairment, regulatory labels indicate that a lower dose and increased monitoring are officially considered.


Q: Is Acroxen safe for people with liver disease?

A: The medication is strictly contraindicated in cases of severe hepatic (liver) failure. Official documentation indicates that it has been associated with rare reports of liver toxicity. For non-severe hepatic impairment, a lower dose and increased monitoring are officially considered.


Q: What are the restrictions on driving while using Acroxen?

A: Regulatory documents contain a caution regarding activities that require full mental alertness. This is because the medication may cause central nervous system effects such as dizziness, lightheadedness, or drowsiness.


Q: Do official sources mention any withdrawal effects from Acroxen?

A: Official product information does not classify this medicine as a controlled substance. Therefore, there are no standard regulatory warnings regarding physical dependence or typical substance withdrawal associated with the use of this medication.


Q: Is Acroxen related to other common medications with similar names?

A: The active ingredient, Naproxen Sodium, is the core component of many brand and generic medicines. These include other products with similar-sounding names, as listed in official drug databases.


Q: Can Acroxen cause sensitivity to sunlight?

A: Regulatory reports confirm that the medication has been associated with rare cases of photoallergy or photosensitivity (increased sensitivity to sunlight).


Q: What is the difference between Acroxen and a standard over-the-counter medicine?

A: The active ingredient is the same in both prescription and over-the-counter (OTC) products. The key difference is regulatory, relating to the maximum available dosage strengths and the maximum daily dose and duration of use permitted without a prescription.


Q: Can Acroxen be taken with antacids?

A: Regulatory warnings state that co-administering certain antacids can delay the absorption of the active ingredient. Because of this, separate timing of doses may be considered to minimize this effect on the body's uptake of the medicine.


Q: What is the official patient information leaflet called for Acroxen?

A: The official patient-facing document accompanying the prescription product in the US is typically referred to as the Patient Medication Guide. This document provides standardized, regulatory-approved safety information for the user.


Q: Is it true that Acroxen can cause ringing in the ears?

A: Tinnitus, which is described as a ringing or buzzing in the ears, is listed in official documents as one of the commonly reported adverse reactions associated with this medicine.

How should Acroxen be stored and disposed of?

Storage Conditions

Acroxen must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), with excursions permitted up to 30 C [1, 5]. The tablets must be kept in a well-closed, light-resistant container and protected from excessive heat (above 40 C) and high humidity [1, 5]. A mandatory requirement is to keep the medicine out of the reach of children [1, 2].

Disposal Requirements

Disposal of any unused or expired Acroxen must comply with local requirements [2]. The primary regulatory recommendation for medicines not on the FDA's flush list is to use a drug take-back program [6, 7]. If take-back options are unavailable, the medicine must be mixed with an unappealing substance (such as dirt) and placed in a sealed bag before being disposed of in the household trash [7].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acroxen found in:

A-Z Index: